REPLY
8.3.2024 09:31:35 CET | Business Wire | Press release
Reply has been ranked among the leading providers of "Salesforce-related Services in Europe 2024" in the PAC Innovation RADAR, an industry study by the independent research and consulting company PAC. In the report, Reply received the highest "Best in Class" award in five industries: Energy & Utilities, Financial Services, Communication & Media, Retail and Manufacturing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240308650974/en/
The PAC INNOVATION RADAR is an instrument for the holistic evaluation of software and ICT service providers from the independent research and consulting company PAC. In the PAC INNOVATION RADAR for Salesforce-related services in Europe, Reply was awarded "Best in Class" in five sectors. (Photo: Business Wire)
The study evaluates the service performance of international software and ICT service providers implementing Salesforce projects in specific IT market segments. Based on pre-defined criteria, PAC analyzes the strategy, development, and market position of the providers and assesses their performance and competencies. For IT decision makers, the PAC RADAR provides valuable guidance in selecting the appropriate service partner.
In the Energy & Utilities, Financial Services, Communication & Media, Retail and Manufacturing sectors, Reply was once again awarded "Best in Class" for its outstanding expertise and market strength in Salesforce-related services. A Salesforce partner since 2005, Reply uses the Salesforce platform to implement effective, customised cloud solutions to ensure customer success worldwide.
Thanks to its companies highly specialised in Salesforce technology, Arlanis Reply, Open Reply, Retail Reply and Power Reply, and more than 900 Salesforce certifications, Reply's competencies cover the entire Salesforce offering: Sales, Service and Marketing, B2B and B2C Commerce, Integration with Mulesoft and Analytics with Tableau. In addition, Reply's experts work with Salesforce extensions for CPQ, Field Service Lightning, Pardot and Einstein AI.
Nick Mayes, Principal Analyst at PAC, commented: "Reply is intensively exploring the market potential of generative AI for enterprises and offers strong expertise in the field of AI and Chat GPT. As a result, Reply has been able to implement innovative Salesforce GPT applications to support the needs of different industry sectors, in a very short time. Reply is leading the development of Salesforce's AI portfolio, creating new business models, products and services for enterprises.”
Filippo Rizzante, CTO of Reply, added: "Reply has an agile and integrated approach to developing cloud-native solutions. Our international teams use the latest technologies, such as AI, to optimise the customer experience and implement projects that have a proven impact on the business success of companies."
Reply has already been named an "EMEA Strategic Partner" by Salesforce in 2023. This designation is given by Salesforce to partner companies that are committed to working across regions and driving strategic issues such as generative AI together with Salesforce. Moreover, Reply is one of the few Salesforce experts in the automotive sector worldwide and has been confirmed by Salesforce as an "Automotive Cloud Launch Partner."
About PAC Innovation RADAR: "Leading Providers of Salesforce-related services in Europe 2024"
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
PAC
PAC is the leading European consulting and analyst firm for the IT industry, a content-based company with a consulting DNA. We accompany software & IT service vendors worldwide on their growth journey. Since 1976, we have helped our clients to understand market dynamics, grow their revenue, and raise their profile. PAC is an analyst-led consultancy with a team of over 100 experts across Europe. We provide market research and analysis on more than 30 countries worldwide, delivered through our portfolio pillars, Guidance, Insights, and Visibility, and our renowned SITSI® research platform. www.pacanalyst.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240308650974/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom